G J Ooi1,2, L Doyle1, T Tie1,2, J M Wentworth1,3, C Laurie1, A Earnest4, M A Cowley5, K Sikaris6, C W le Roux7, P R Burton1, P E O'Brien1, W A Brown1,2. 1. Centre for Obesity Research and Education, Monash University, Melbourne, Victoria, Australia. 2. Monash University Department of Surgery, Alfred Hospital, Melbourne, Victoria, Australia. 3. Walter and Eliza Hall Institute, Melbourne University, Parkville, Victoria, Australia. 4. Department of Epidemiology, SPHPM, Monash University, Melbourne, Victoria, Australia. 5. MODI, Monash University, Melbourne, Victoria, Australia. 6. Melbourne Pathology, East Melbourne, Victoria, Australia. 7. Diabetes Complications Research Centre, University College, Dublin, Ireland.
Abstract
BACKGROUND: Substantial weight loss in the setting of obesity has considerable metabolic benefits. Yet some studies have shown improvements in obesity-related metabolic comorbidities with more modest weight loss. By closely monitoring patients undergoing bariatric surgery, we aimed to determine the effects of weight loss on the metabolic syndrome and its components and determine the weight loss required for their resolution. METHODS: We performed a prospective observational study of obese participants with metabolic syndrome (Adult Treatment Panel III criteria) who underwent laparoscopic adjustable gastric banding. Participants were assessed for all criteria of the metabolic syndrome monthly for the first 9 months, then 3-monthly until 24 months. RESULTS: There were 89 participants with adequate longitudinal data. Baseline body mass index was 42.4±6.2 kg m-2 with an average age was 48.2±10.7 years. There were 56 (63%) women. Resolution of the metabolic syndrome occurred in 60 of the 89 participants (67%) at 12 months and 60 of the 75 participants (80%) at 24 months. The mean weight loss when metabolic syndrome resolved was 10.9±7.7% total body weight loss (TBWL). The median weight loss at which prevalence of disease halved was 7.0% TBWL (17.5% excess weight loss (EWL)) for hypertriglyceridaemia; 11% TBWL (26.1-28% EWL) for high-density lipoprotein cholesterol and hyperglycaemia; 20% TBWL (59.5% EWL) for hypertension and 29% TBWL (73.3% EWL) for waist circumference. The odds ratio for resolution of the metabolic syndrome with 10-12.5% TBWL was 2.09 (P=0.025), with increasing probability of resolution with more substantial weight loss. CONCLUSIONS: In obese participants with metabolic syndrome, a weight loss target of 10-12.5% TBWL (25-30% EWL) is a reasonable initial goal associated with significant odds of having metabolic benefits. If minimal improvements are seen with this initial target, additional weight loss substantially increases the probability of resolution.
BACKGROUND: Substantial weight loss in the setting of obesity has considerable metabolic benefits. Yet some studies have shown improvements in obesity-related metabolic comorbidities with more modest weight loss. By closely monitoring patients undergoing bariatric surgery, we aimed to determine the effects of weight loss on the metabolic syndrome and its components and determine the weight loss required for their resolution. METHODS: We performed a prospective observational study of obeseparticipants with metabolic syndrome (Adult Treatment Panel III criteria) who underwent laparoscopic adjustable gastric banding. Participants were assessed for all criteria of the metabolic syndrome monthly for the first 9 months, then 3-monthly until 24 months. RESULTS: There were 89 participants with adequate longitudinal data. Baseline body mass index was 42.4±6.2 kg m-2 with an average age was 48.2±10.7 years. There were 56 (63%) women. Resolution of the metabolic syndrome occurred in 60 of the 89 participants (67%) at 12 months and 60 of the 75 participants (80%) at 24 months. The mean weight loss when metabolic syndrome resolved was 10.9±7.7% total body weight loss (TBWL). The median weight loss at which prevalence of disease halved was 7.0% TBWL (17.5% excess weight loss (EWL)) for hypertriglyceridaemia; 11% TBWL (26.1-28% EWL) for high-density lipoprotein cholesterol and hyperglycaemia; 20% TBWL (59.5% EWL) for hypertension and 29% TBWL (73.3% EWL) for waist circumference. The odds ratio for resolution of the metabolic syndrome with 10-12.5% TBWL was 2.09 (P=0.025), with increasing probability of resolution with more substantial weight loss. CONCLUSIONS: In obeseparticipants with metabolic syndrome, a weight loss target of 10-12.5% TBWL (25-30% EWL) is a reasonable initial goal associated with significant odds of having metabolic benefits. If minimal improvements are seen with this initial target, additional weight loss substantially increases the probability of resolution.
Authors: David E Laaksonen; Hanna-Maaria Lakka; Leo K Niskanen; George A Kaplan; Jukka T Salonen; Timo A Lakka Journal: Am J Epidemiol Date: 2002-12-01 Impact factor: 4.897
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Wendy A Brown; Julia Moszkowicz; Leah Brennan; Paul R Burton; Margaret Anderson; Paul E O'Brien Journal: Obes Surg Date: 2013-10 Impact factor: 4.129
Authors: Viktoria L Gloy; Matthias Briel; Deepak L Bhatt; Sangeeta R Kashyap; Philip R Schauer; Geltrude Mingrone; Heiner C Bucher; Alain J Nordmann Journal: BMJ Date: 2013-10-22
Authors: Geraldine J Ooi; Paul R Burton; Arul Earnest; Cheryl Laurie; William W Kemp; Peter D Nottle; Catriona A McLean; Stuart K Roberts; Wendy A Brown Journal: Obes Surg Date: 2018-02 Impact factor: 4.129
Authors: Geraldine J Ooi; Arul Earnest; Lisa Doyle; Cheryl Laurie; John M Wentworth; Ken Sikaris; Carel W le Roux; Paul R Burton; Paul E O'Brien; Wendy A Brown Journal: Obes Surg Date: 2018-05 Impact factor: 4.129
Authors: John M Wentworth; Chloe Cheng; Cheryl Laurie; Stewart Skinner; Paul R Burton; Wendy A Brown; Paul E O'Brien Journal: Obes Surg Date: 2018-04 Impact factor: 4.129
Authors: Jose-Maria Jiménez; Miguel-Angel Carbajo; María López; María-José Cao; Jaime Rúiz-Tovar; Sara García; María-José Castro Journal: Int J Environ Res Public Health Date: 2020-08-13 Impact factor: 3.390